Mosby's 2014 Nursing Drug Reference (270 page)

BOOK: Mosby's 2014 Nursing Drug Reference
13.98Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

miglitol (Rx)

(mig′lih-tol)

Glyset

Func. class.:
Oral hypoglycemic

Chem. class.:
α-Glucosidase inhibitor

ACTION:

Delays digestion and absorption of ingested carbohydrates, which results in a smaller rise in blood glucose after meals; does not increase insulin production

USES:

Type 2 diabetes mellitus

CONTRAINDICATIONS:

Hypersensitivity, diabetic ketoacidosis, cirrhosis, inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, chronic intestinal disease, ileus

Precautions:
Pregnancy (B), breastfeeding, children, renal/hepatic disease

DOSAGE AND ROUTES
Calculator

• Adult:
PO
25 mg tid initially, with 1st bite of meal; maintenance dose may be increased to 50 mg tid; may be increased to 100 mg tid if needed with dosage adjustment at 4- to 8-wk intervals

Available forms:
Tabs 25, 50, 100 mg

Administer:

• 
Tid with first bite of each meal

SIDE EFFECTS

GI:
Abdominal pain, diarrhea, flatulence
,
hepatotoxicity

HEMA:
Low iron

INTEG:
Rash

RESP:
Pneumatosis cystoides, intestinalis

PHARMACOKINETICS

Peak 2-3 hr, not metabolized, excreted in urine as unchanged product, half-life 2 hr

INTERACTIONS

Decrease:
levels of digoxin, propranolol, ranitidine

Decrease:
miglitol levels—digestive enzymes, intestinal adsorbents; do not use together

Drug/Food

Increase:
diarrhea—carbohydrates

NURSING CONSIDERATIONS
Assess:

• 
Hypo/hyperglycemia;
even though product does not cause hypoglycemia, if patient receiving sulfonylureas or insulin, hypoglycemia may be additive (rare)

• 
Blood glucose levels, hemoglobin, A1c LFTs; if hypoglycemia occurs with monotherapy, treat with glucose

Perform/provide:

• 
Storage in tight container at room temp

Evaluate:

• 
Therapeutic response: decreased signs, symptoms of diabetes mellitus (polyuria, polydipsia, polyphagia; clear sensorium, absence of dizziness; stable gait); improved blood glucose, A1c

Teach patient/family:

• 
About the symptoms of hypo/hyperglycemia, what to do about each; that, during periods of stress, infection, or surgery, insulin may be required

• 
That medication must be taken as prescribed; about consequences of discontinuing medication abruptly

• 
To avoid OTC medications unless approved by health care provider

• 
That diabetes is lifelong; that product is not a cure

• 
To carry ID for emergency purposes

• 
That diet and exercise regimen must be followed

• 
About GI side effects

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

HIGH ALERT
milrinone (Rx)

(mill′rih-nohn)

Func. class.:
Inotropic/vasodilator agent with phosphodiesterase activity

Chem. class.:
Bipyridine derivative

ACTION:

Positive inotropic agent; increases contractility of cardiac muscle with vasodilator properties; reduces preload and afterload by direct relaxation on vascular smooth muscle

USES:

Short-term management of advanced heart failure that has not responded to other medication

Unlabeled uses:
Adolescents, children, infants

CONTRAINDICATIONS:

Hypersensitivity to this product, severe aortic disease, severe pulmonic valvular disease, acute MI

Precautions:
Pregnancy (C), breastfeeding, children, geriatric patients, renal/hepatic disease, atrial flutter/fibrillation

DOSAGE AND ROUTES
Calculator

• Adult:
IV BOL
50 mcg/kg given over 10 min; start inf of 0.375-0.75 mcg/kg/min

• Adolescent/child/infant (unlabeled):
IV
50-75 mcg/kg over 10-60 min then 0.5-0.75 mcg/kg/min

Renal dose

• Adult:
IV
CCr 41-50 ml/min, 0.43 mcg/kg/min, titrate up; CCr 31-40 ml/min, 0.38 mcg/kg/min, titrate up; CCr 21-30 ml/min, 0.33 mcg/kg/min, titrate up; CCr 11-20 ml/min, 0.08 mcg/kg/min; CCr 6-10 ml/min, 0.23 mcg/kg/min; CCr ≤5 ml/min, 0.20 mcg/kg/min; max for all doses 0.75 mcg/kg/min

Available forms:
Inj 1 mg/ml; premixed inj 200 mcg/ml in D
5
W

Administer:

• 
Potassium supplements if ordered for potassium levels <3 mg/dl

Direct IV route

• 
Give IV loading dose undiluted over 10 min, use inf device

Continuous IV route

• 
Dilute 20-mg vial with 80, 113, 180 ml of 0.45% NaCl, 0.9% NaCl, or D
5
W to a conc of 200, 150, 100 mcg/ml respectively

• 
Titrate rate based on hemodynamic and clinical response, use inf device

• 
Precipitation will form when furosemide is injected into line with milrinone

Y-site compatibilities:
Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, atenolol, atracurium, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, digoxin, diltiazem, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, ertapenem, erythromycin, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, methohexital, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, mitoXANtrone, morphine, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride/phosphates, prochlorperazine, promethazine, propofol, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, torsemide, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid

SIDE EFFECTS

CV:
Dysrhythmias,
hypotension, chest pain,
PVCs

GI:
Nausea, vomiting, anorexia, abdominal pain,
hepatotoxicity, jaundice

HEMA:
Thrombocytopenia

MISC:
Headache, hypokalemia, tremor, inj site reactions

PHARMACOKINETICS

IV:
Onset 2-5 min, peak 10 min, duration variable; terminal half-life 2.3 hr; metabolized in liver; excreted in urine as product (83%), metabolites (12%)

INTERACTIONS

Increase:
effects of antihypertensives, diuretics

NURSING CONSIDERATIONS
Assess:

 
ECG continuously during IV; ventricular dysrhythmia can occur

• 
B/P, pulse q5min during inf; if B/P drops 30 mm Hg, stop inf, call prescriber

• 
Electrolytes: potassium, sodium, chloride, calcium; renal studies: BUN, creatinine; blood studies: platelet count

• 
ALT, AST, bilirubin daily

• 
I&O ratio, weight daily; diuresis should increase with continuing therapy

• 
If platelets are <150,000/mm
3
, product is usually discontinued and another product started

Evaluate:

• 
Therapeutic response: increased cardiac output, decreased PCWP, adequate CVP; decreased dyspnea, fatigue, edema, ECG

Teach patient/family:

• 
To report angina immediately during inf

• 
To report headache, which can be treated with analgesics

TREATMENT OF OVERDOSE:

Discontinue product, support circulation

Other books

Point of Law by Clinton McKinzie
The Fall of the Imam by Nawal el Saadawi
Inked (Tattoos and Leather) by Holland, Jaymie
Red Eye - 02 by James Lovegrove